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Lytic (osteoclastic) bone lesions and hypercalcaemia
are characteristic features of multiple myeloma
(MM) and are related to the extent and the severity
of the disease (Durie & Salmon, 1975). Therefore, a
careful evaluation of myeloma osteoclastic potential
is of major interest in prognosis. However this
remains difficult, especially because bone
radiography is often deficient at an early stage of
the disease and does not give any clue to the
instantaneous rate of osteoclastic bone resorption in
the whole body. Recent work has shown that bone
lesions are due to osteoclast activating factor
(OAF) production by myeloma cells (Mundy et al.,
1974a; Gailani et al., 1976). This is well supported
by data from a large number of bone biopsies
showing that osteoclasts are present in increased
number in resorption lacunae only in bone lying
adjacent to collections of myeloma cells (Mundy
et al., 1974a; Valentin-Opran et al., 1982).
Therefore, it was logical to think that significant
OAF production in vitro could be the best
indication of early myeloma osteoclastic activity.
Unfortunately, OAF production is evaluated in
vitro by a very complex bioassay procedure based
on short-term liquid cultures of myeloma cells
(Raisz, 1965). This difficulty was well illustrated by
conflicting results recently published by authors
who tried to relate bone resorbing activity
measured in vitro to the presenting features of
myeloma patients (especially the extent of bone
lesions and disease activity) (Schecter et al., 1980;
Durie et al., 1981). Other explanations of these
discrepancies could be that some myeloma patients
have a very indolent disease at diagnosis in spite of
lesions on bone radiography (Alexanian, 1980),
suggesting that the release of a bone resorbing
activity by myeloma cells is not a continuous
process or may be regulated by accessory cells. This
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is now a critical point because potent anti-
osteoclastic drugs such as diphosphonates were
recently proven to be effective in MM as a long
term treatment of osteoclastic resorption (Delmas et
al., 1982). In future, the early detection of myeloma
patients with very active bone resorption will be
necessary, as a rational prerequisite for the
combination of anticancer and antiosteoclastic
drugs as a primary treatment of MM.
In a recent effort to improve the serial evaluation
of myeloma osteoclastic bone lesions, we applied to
MM a simple test, the salmon calcitonin (SCT)
induced hypocalcaemia (A Ca) test (=SCT ACa
test) which appears to give reliable information on
bone disease activity and prognosis of myeloma
patients (Bataille & Sany 1982, Bataille et al.,
1983). To more thoroughly document the bone
status of some of our myeloma patients, we have
performed a radiolabelled bone resorption assay in
27 previously untreated patients, the results of
which are presented herein.
MM was defined as by the diagnostic criteria of
the Southwest Oncology Group (Durie & Salmon
1977). The extent of lytic bone lesions on bone
radiography was as following: no lesion (8 cases)
one lesion (3 cases), limited lesions (8 cases) and
extensive lesions with major fractures (8 cases). In
this series of patients, one moderate and one severe
(>3mmoll-1) hypercalcaemia were observed. The
instantaneous rate of bone resorption in the whole
body was evaluated simultaneously in vivo in 15
patients.
Bone marrow samples were aspirated into a
heparinized syringe and marrow particles were
immediately dispersed by syringing with
progressively smaller gauge needles (19, 21, 23 and
25G). The sample was then mixed in an equal
volume of Hanks balanced salt solution HBSS
without calcium and magnesium and a suspension
enriched for myeloma cells was obtained by
differential centrifugation on Ficoll-paque density
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solution 1.077gcm-2. The floating fraction of cells
was collected and washed 3 x in HBSS. The final
pellet was suspended in culture medium at 5 x 105
viable cells ml-'. The viability of nucleated cells,
estimated by trypan blue exclusion, was always
>90%. The percentage of myeloma cells was
evaluated on cytocentrifuge smears, stained with
May-Grunwald Giemsa. Cells were adjusted to
5 x 10 ml-I in RPM1 1640 supplemented with 10%
horse serum and as previously described by Pike &
Robinson (1971). Cells were cultured in falcon
plastic tissue culture dishes (25cm2, 5ml/dish) for 3
days in a water jacketed incubator at 37°C with an
atmosphere of 5% CO2 in air. Supernatants were
harvested after centrifugation, stored at -20°C and
assayed for bone resorbing activity. Culture
medium (without cells) was used as a negative
control. As a positive control for myeloma OAF,
we used supernatants from the human myeloma cell
line RPM1 8226 (a gift of Dr B.G.M. Durie). As
previously described by Mundy et al. 1974b, this
cell line has a potent bone resorbing activity easily
detectable in vitro.
Supernatants derived from the short-term
suspension cultures were boiassayed for bone
resorbing activity using the radiolabelled bone
resorption assay described by Raisz (1965). Briefly,
pregnant rats were injected i.p. with 45Ca on the
18th day of gestation. The following day, the rats
were killed, the faetuses removed and the long
bones dissected free of soft tissues. The bones were
precultured for 24h in control medium to allow for
exchange of loosely bound 45Ca. The bones were
then cultured either in control medium or
conditioned medium (by myeloma cells or RPMI
8226). After 2 days, 45Ca release from bone into
medium was measured and a ratio of 45Ca released
into conditioned versus control medium generated.
For each patient, 4-12 equal pairs of bones were
available. For statistical analysis, we used the
Wilcoxon sign rank test for matched pairs (two-
tailed test) when more than 6 pairs of bones were
available, a ratio significantly >1 indicating the
presence of significant bone resorbing activity.
When only 5 or 6 pairs of bones were available, the
detection of a bone resorbing activity was
considered as significant/positive if each tested pair
gave a ratio >1 (P=0.05 and P=0.062
respectively).
For statistical comparison, we used the Wilcoxon
test (sum rank test) and the Fisher exact test).
A significant bone resorbing activity was always
detected in supernates of RPMI 8226, with stable
and reproducible results throughout the study (data
not shown). By themselves, these data are
interesting, emphasizing the interest of this human
myeloma cell line as a simple and positive control
for myeloma OAF studies.
In 5 patients with <10% of myeloma cells in
their bone-marrow and either zero or single lytic
bone lesions, no significant bone resorbing activity
was detected. Of the remaining 22 patients, a
significant activity was found in 6 (27% of cases).
A careful comparison, in terms of osteolytic and
disease activity, was made between these 2 groups.
An important point was that the detection (or not)
of a bone resorbing activity in this study could not
be explained by differences in the percentage of
malignant plasma cells. In patients with a
significant bone resorbing activity, the percentages
of myeloma cells ranged from 10-53 (mean/median
values, 32+ 18%/25%), percentages very closed to
those of the other group (range 10-88,
mean/median values, 37+25%/26%). On the other
hand, significant differences were observed between
the 2 groups when presenting features and the
subsequent follow-up of these patients were
compared. (i) Patients with in vitro bone resorbing
activity had more lytic bone lesions on radiography
than patients without detectable activity:
mean/median number of bone lesions per patient,
9/6 versus 3/1 (P<0.05). (ii) An abnormal SCT
ACa test in favour of a high rate of bone
resorption was noted in 100% of patients with a
significant in vitro bone resorbing activity versus
44% for patients without detectable activity
(P<0.05). (iii) The patient with severe
hypercalcaemia had a significant bone resorbing
activity. (iv) Finally, a progression of the disease
was observed in 4/6 patients with detectable bone
resorbing activity. All these patients had .4 bone
lesions. In the group of patients without detectable
bone resorbing activity, patients presenting with
bone lesions on radiography did not have lytic
progression.
Comments
These results show that all patients with detectable
in vitro bone resorbing activity had very active bone
disease and that they could take advantage of anti-
osteoclastic drugs such as new diphosphonates.
Indeed, these patients had numerous lytic bone
lesions with major fractures, high myeloma cell
mass and were found to be very sensitive to salmon
calcitonin, using the SCT ACa test. Reciprocally,
patients without detectable in vitro bone resorbing
activity usually had a more indolent disease. This
good agreement between in vitro OAF production
(without any correction for the exact percentage of
myeloma cells) and disease activity could be
explained, in part, by the fact that only high OAF
producers were probably detected by our bioassay.
Indeed, as previously described (see above),
myeloma cells were cultured at a very low density
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studies using high density cell cultures (i.e. from 106
to 2 x 106 cellsm1-1) (Mundy et al., 1974a; Schecter
et al., 1980). Furthermore, conditioned media were
tested at a 1/2 dilution with control medium. It was
striking to compare the small percentage of
myeloma patients with significant in vitro bone
resorbing activity observed in the current study
with higher percentages found in previous works
(Mundy et al., 1974a; Schecter et al., 1980). In spite
of an overall agreement between in vitro bone
resorbing activity and bone disease activity, a major
discrepancy was observed in 3 patients. In these
patients, no bone resorbing activity was detected in
vitro although they had active bone disease marked
by extensive bone lesions on radiography. No clear
explanation can be given for that. Since a
significant bone resorbing activity was
simultanesouly detected in media conditioned by
RPMI 8226, a technical failure can be eliminated.
An explanation could be that some presentations of
OAF are not detectable by this kind of bioassay.
Another explanation could be the production either
of short-lived OAF indetectable at 3 days of culture
or of an OAF inhibitor. Further investigations will
be necessary to clarify these particular points.
However, the relative subsequent indolence of these
patients should be noted.
We conclude that in vitro studies of myeloma
bone resorbing activity remain difficult to use on a
routine basis. However, considering that the
detection of a bone resorbing activity in vitro was
invariably associated with active disease, this
bioassay (i) could be useful to discriminate between
smouldering/indolent myeloma and overt/active
myeloma and (iii) could warrant the use of anti-
osteoclastic drugs such as diphosphonates in case of
positive results.
We thank F. Caulin (Armour laboratory), Sandoz
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